KR20200078483A - 간암 치료를 위한 조성물 및 방법 - Google Patents

간암 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20200078483A
KR20200078483A KR1020207008272A KR20207008272A KR20200078483A KR 20200078483 A KR20200078483 A KR 20200078483A KR 1020207008272 A KR1020207008272 A KR 1020207008272A KR 20207008272 A KR20207008272 A KR 20207008272A KR 20200078483 A KR20200078483 A KR 20200078483A
Authority
KR
South Korea
Prior art keywords
pembrolizumab
talimogen
antigen
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207008272A
Other languages
English (en)
Korean (ko)
Inventor
제니퍼 로렌 갠서트
스와미나단 무루가판
마이클 케빈 울프
Original Assignee
머크 샤프 앤드 돔 코포레이션
암젠 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 코포레이션, 암젠 인크 filed Critical 머크 샤프 앤드 돔 코포레이션
Publication of KR20200078483A publication Critical patent/KR20200078483A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020207008272A 2017-10-27 2018-10-26 간암 치료를 위한 조성물 및 방법 Ceased KR20200078483A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762578071P 2017-10-27 2017-10-27
US62/578,071 2017-10-27
PCT/US2018/057731 WO2019084418A1 (en) 2017-10-27 2018-10-26 COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER CANCER

Publications (1)

Publication Number Publication Date
KR20200078483A true KR20200078483A (ko) 2020-07-01

Family

ID=64453576

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207008272A Ceased KR20200078483A (ko) 2017-10-27 2018-10-26 간암 치료를 위한 조성물 및 방법

Country Status (13)

Country Link
US (1) US20200353022A1 (https=)
EP (1) EP3700544A1 (https=)
JP (1) JP2021501150A (https=)
KR (1) KR20200078483A (https=)
CN (1) CN111278448A (https=)
AR (1) AR113805A1 (https=)
AU (1) AU2018355519A1 (https=)
BR (1) BR112020007494A2 (https=)
CA (1) CA3075294A1 (https=)
MX (1) MX2020003388A (https=)
SG (1) SG11202002123XA (https=)
TW (1) TWI817958B (https=)
WO (1) WO2019084418A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
US12310999B2 (en) * 2017-04-28 2025-05-27 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics
CN114191547A (zh) * 2021-12-23 2022-03-18 中山大学 仑伐替尼与pd-1单抗联用在制备抗肝癌药物中的应用
WO2025085538A1 (en) * 2023-10-17 2025-04-24 Lanier Biotherapeutics, Inc. Alarmin binding molecules and treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE60115600T2 (de) 2000-01-21 2006-07-20 Biovex Ltd. Virusstämme für die onkolytische behandlung von krebs
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
ES2676205T3 (es) 2011-03-31 2018-07-17 Merck Sharp & Dohme Corp. Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
JP6457940B2 (ja) 2012-08-30 2019-01-23 アムジエン・インコーポレーテツド 単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
DK3169341T3 (da) * 2014-07-16 2019-08-05 Transgene Sa Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
AU2015289081B2 (en) * 2014-07-16 2020-02-06 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
US10751412B2 (en) 2015-05-29 2020-08-25 Merck Sharp & Dohme Corp. Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
PL3426271T3 (pl) * 2016-03-10 2025-11-24 Cg Oncology, Inc. Sposoby leczenia guzów litych terapią skojarzoną
WO2018111902A1 (en) * 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
US12310999B2 (en) * 2017-04-28 2025-05-27 Merck Sharp & Dohme Corp. Biomarkers for cancer therapeutics

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트

Also Published As

Publication number Publication date
SG11202002123XA (en) 2020-04-29
CN111278448A (zh) 2020-06-12
TW201922273A (zh) 2019-06-16
WO2019084418A1 (en) 2019-05-02
AR113805A1 (es) 2020-06-10
RU2020111709A (ru) 2021-11-29
BR112020007494A2 (pt) 2020-11-03
RU2020111709A3 (https=) 2022-04-26
US20200353022A1 (en) 2020-11-12
MX2020003388A (es) 2020-08-03
JP2021501150A (ja) 2021-01-14
AU2018355519A1 (en) 2020-03-26
EP3700544A1 (en) 2020-09-02
CA3075294A1 (en) 2019-05-02
TWI817958B (zh) 2023-10-11

Similar Documents

Publication Publication Date Title
US12534530B2 (en) Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
US20260027205A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
US20260109768A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
KR102662228B1 (ko) 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
IL301533A (en) Stable compositions of programmed death receptor 1 (PD-1) antibodies and hyaluronidase variants and parts thereof and methods of using them
CN110869765A (zh) 组合疗法
TWI817958B (zh) 用於治療肝癌之組合物及方法
WO2017165125A1 (en) Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer
JP2024001071A (ja) びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法
EP3856251B1 (en) Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
CN121548431A (zh) 包含偶联物的药物组合的治疗方法和用途
US20240182583A1 (en) Combination of anti-galectin-9 antibodies and chemotherapeutics for use in cancer therapy
RU2802962C2 (ru) Композиции и способы лечения рака печени
EP4494654A1 (en) Pharmaceutical composition of anti-tim-3 antibody and hypomethylating agent
CN119031933B (zh) 蛋白酶体抑制剂与抗pd-1抗体的药物组合
US20230322929A1 (en) Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy
US20260116979A1 (en) Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
CN121335710A (zh) 重组溶瘤病毒与检查点抑制剂的组合用于治疗癌症
CN121443321A (zh) 治疗组合及其用途和治疗方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200320

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211022

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240401

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240604

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20240401

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I